‘Lucid Diagnostics: Analysts See 257% Upside Potential’ -TipRanks Report. BZ NOTE: PAVmed Owns Stake In Lucid Diagnostics
https://blog.tipranks.com/lucid-diagnostics-analysts-see-257-upside-potential/
51 Biggest Movers From Yesterday
Gainers
Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
Ascendiant Capital Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $16
Ascendiant Capital analyst Edward Woo initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $16.
Lucid Diagnostics, PAVmed Majority-Owned Subsidiary Highlight Launch Of Its EsoGuard Telemedicine Program In Partnership With Telemedicine Co. UpScriptHealth, No Terms Disclosed
Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer
61 Biggest Movers From Yesterday
Gainers
Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share.
42 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share.
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid") a commercial-stage, cancer prevention
BTIG Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $14
BTIG analyst Mark Massaro initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $14.
Canaccord Genuity Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Kyle Mikson initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $18.